Journal article
Role of Phosphodiesterase-5 Inhibitors in Heart Failure: Emerging Data and Concepts
Current heart failure reports, v 10(1), pp 26-35
01 Mar 2013
PMID: 23114592
Abstract
Novel treatment of congestive heart failure (HF) involves utilizing unique pathways to improve upon contemporary therapies. Increasing the availability of cyclic guanosine monophosphate (cGMP) by inhibition of phosphodiesterase-5 (PDE5) is a relatively new, but promising therapeutic strategy. Preclinical studies suggest a favorable myocardial effect of PDE5 inhibitors by blocking adrenergic, hypertrophic and pro-apoptotic signaling, thereby supporting their use in HF. The clinical benefits of acute and chronic PDE5 inhibition on lung diffusion capacity, exercise performance and ejection fraction in humans are emerging and appear promising. Larger, controlled trials are now on-going to assess the safety, efficacy and tolerability of PDE5 inhibitors on morbidity and mortality in patients with both systolic and diastolic heart failure. If the results of these trials are positive, a new avenue for the treatment of HF will open, which will help curtail the societal effects of this costly and morbid disease.
Metrics
10 Record Views
14 citations in Scopus
Details
- Title
- Role of Phosphodiesterase-5 Inhibitors in Heart Failure: Emerging Data and Concepts
- Creators
- Manreet Kanwar - Allegheny General HospitalRicha Agarwal - Allegheny General HospitalMegan Barnes - Allegheny General HospitalJames Coons - Allegheny General HospitalAmresh Raina - Allegheny General HospitalGeorge Sokos - Allegheny General HospitalSrinivas Murali - Allegheny General HospitalRaymond L. Benza - Allegheny General Hospital
- Publication Details
- Current heart failure reports, v 10(1), pp 26-35
- Publisher
- Current Science Inc
- Number of pages
- 10
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate); Cardiology
- Scopus ID
- 2-s2.0-84873722229
- Other Identifier
- 991021932189004721